Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
106last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
Barchart101d agobearish
HIMS Stock in Focus as FTC Lawsuit Takes Aim at Hims & Hers Business PracticesSimply Wall St.101d agobearish
Hims & Hers Health (HIMS) Faces FTC Lawsuit Over Health Data And BillingThe Wall Street Journal102d agoneutral
FTC Sues Hims & Hers, Alleging Unlawful Sharing of Data, Deceptive BillingReuters102d agoneutral
Exclusive-US FTC suing Hims & Hers for sending user health info to Meta, SnapBenzinga106d agoneutral
FDA Panel Narrowly Backs Four Peptides - Hims & Hers Stock in the SpotlightInvestor's Business Daily108d agoneutral
Hims, The Surprise Winner Of The FDA Showdown With Peptides, Bounds HigherInvestor's Business Daily115d agoneutral
This Trade Offers Two Ways To Profit From Hims & Hers StockSimply Wall St.159d agoneutral
Hims And Hers Health Expands With Eucalyptus Acquisition And Global Growth ProspectsProactive166d agoneutral
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofAReuters171d agoneutral
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiryStockStory172d agoneutral
5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings CallMotley Fool177d agobearish
Hims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign?24/7 Wall St.179d agobearish
BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations